 |
Alder Biopharmaceutical, Inc.
Uniquely identifies, develops, and manufactures novel antibody therapeutics for autoimmune and inflammatory diseases. The company also enables partners through out-licensing of its technologies.
www.alderbio.com |
 |
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA)
Inhaled therapies for acute and intermittent conditions employing a device that rapidly delivers pure drug
www.alexza.com |
 |
Antipodean Pharmaceuticals, Inc.
Drug development for oral therapies for neurodegenerative diseases associated with mitochondrial dysfunction
www.antipodeanpharma.com |
 |
KAI Pharmaceuticals, Inc.
Development of selective modulators of protein kinase isozymes, initially to treat ischemic reperfusion injury
www.kaipharmaceuticals.com |
 |
Labcyte Inc.
Instrumentation using focused acoustic energy to accurately dispense very small quantities of high-value fluids for pharmaceutical research
www.labcyte.com |
 |
Locus Pharmaceuticals, Inc.
Computational drug discovery to design small molecule therapeutic compounds for protein targets
www.locuspharma.com |
 |
NeurAxon, Inc.
Developing next generation pain therapeutics
www.neuraxon.com |
 |
Phenomix Corporation
Drug discovery and development company with a portfolio of therapeutic programs in metabolic syndrome and immune disease
www.phenomix.com |
 |
ProActa, Inc.
Focused on the treatment of tumors by exploiting their abnormally low concentrations of oxygen (hypoxia)
www.proacta.com |
 |
Proteolix, Inc.
A biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target the proteasome and the control of protein turnover in cells
www.proteolix.com |
 |
PTC Therapeutics, Inc.
Development of orally active small molecules that modulate post-transcriptional processes
www.ptcbio.com |
|
Relypsa, Inc.
Discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease.
www.relypsa.com |
 |
Seattle Genetics, Inc. (Nasdaq: SGEN)
Development of monoclonal antibody (mAb)-based therapeutics for cancer and other human diseases
www.seagen.com |
